OOIR: Observatory of International Research

Papers

(The TQCC of Pediatric Blood & Cancer is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Characterization of COVID‐19 disease in pediatric oncology patients: The New York‐New Jersey regional experience	84
COVID‐19 and children with cancer: Parents’ experiences, anxieties and support needs	75
Neuroblastoma	72
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials	51
Ewing sarcoma	48
Impacts of COVID‐19 on caregivers of childhood cancer survivors	47
2023 ASPHO Conference Paper and Poster Index	47
Clinical presentations and outcomes of children with cancer and COVID‐19: A systematic review	47
ABSTRACTS	41
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studi	38
Late effects of radiation therapy in pediatric patients and survivorship	37
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial	35
Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase	34
ORAL ABSTRACTS	34
Acute lymphoblastic leukemia	34
Children and young adults hospitalized for severe COVID‐19 exhibit thrombotic coagulopathy	34
ABSTRACTS	33
No increase in psychosocial stress of Dutch children with cancer and their caregivers during the first months of the COVID‐19 pandemic	32
Sarcopenia is a prognostic outcome marker in children with high‐risk hepatoblastoma	31
Homestead together: Pediatric palliative care telehealth support for rural children with cancer during home‐based end‐of‐life care	30
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project	30
Severe adverse events during sirolimus “off‐label” therapy for vascular anomalies	29
PediCARE: Development of a poverty‐targeted intervention for pediatric cancer	28
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years	26
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC‐042)	26

Second tumor risk in children treated with proton therapy	26
SIOP ABSTRACTS	25
How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C	25
Long‐term health‐related quality of life in young childhood cancer survivors and their parents	24
How we approach the diagnosis and management of complex lymphatic anomalies	24
Social determinants of health and pediatric cancer survival: A systematic review	24
Sickle cell disease and COVID‐19: Susceptibility and severity	23
Clinical prognostic factors in pediatric adrenocortical tumors: A meta‐analysis	23
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low‐grade glioma	23
Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission	22
Long‐term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy	22
Virtual visits as long‐term follow‐up care for childhood cancer survivors: Patient and provider satisfaction during the COVID‐19 pandemic	22
Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations	22
Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States	21
Treatment of acute myeloid leukemia in children: A practical perspective	21
Rhabdomyosarcoma	21
Prevention of acute and delayed chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline	21
A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high‐risk pediatric patients	21
Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom	21
Sickle cell disease and social determinants of health: A scoping review	20
The role of interferon‐gamma and its signaling pathway in pediatric hematological disorders	20
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pedia	20
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group	20
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?	20
COVID‐19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study	20
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN)	19
Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemia	19
A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study	19
Impact of COVID‐19 on adolescent and emerging adult brain tumor survivors and their parents	19
A community‐based trial of a psychosocial eHealth intervention for parents of children with cancer	19
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma	19
Treatment abandonment: A report from the collaborative African network for childhood cancer care and research—CANCaRe Africa	19
¹⁸F‐FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta‐analysis	19
Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10‐year review	18
Discrepancies between F‐18‐FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis	18
Implementation of daily patient‐reported outcome measurements to support children with cancer	18
Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical co	18
Pediatric classical Hodgkin lymphoma	17
Interdependent functions of communication with adolescents and young adults in oncology	17
In vivo evaluation of the lysine‐specific demethylase (KDM1A/LSD1) inhibitor SP‐2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consor	17
Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia	17
Eltrombopag in children with severe aplastic anemia	17
Consensus recommendations from the EXPeRT/PARTNER groups for the diagnosis and therapy of sex cord stromal tumors in children and adolescents	16
Implementing newborn screening for sickle cell disease in Korle Bu Teaching Hospital, Accra: Results and lessons learned	16
Pseudohypoxic pheochromocytomas and paragangliomas dominate in children	16
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab	16
Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations	16
Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia	16
Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children	16
A review of the experience with pediatric written requests issued for oncology drug products	16

Prevention and treatment of anticipatory chemotherapy‐induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update	16
“Money was the problem”: Caregivers' self‐reported reasons for abandoning their children's cancer treatment in southwest Uganda	16
How we approach malignant infantile osteopetrosis	16
Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents	15
Effects of hydroxyurea on brain function in children with sickle cell anemia	15
Clinical evaluation of late outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER 2 study	15
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate‐risk Hodgkin lymphoma treated with chemo‐radiation therapy: FDG‐PET parameter analysis in a subgroup f	15
Family functioning and adaptation following pediatric brain tumor: A systematic review	15
Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study	15
Factors affecting COVID‐19 vaccine hesitancy in parents of children with cancer	15
Comparison of neuropsychological functioning in pediatric posterior fossa tumor survivors: Medulloblastoma, low‐grade astrocytoma, and healthy controls	15
Acceptability and feasibility of survivorship care plans and an accompanying mobile health intervention for adolescent and young adult survivors of childhood cancer	15
How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group	15
Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review	15
Long‐term results from the multicentric European randomized phase 3 trial CWS/RMS‐96 for localized high‐risk soft tissue sarcoma in children, adolescents, and young adults	14
Tumor surveillance for children and adolescents with cancer predisposition syndromes: The psychosocial impact reported by adolescents and caregivers	14
Pleuropulmonary blastoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations	14
Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia	14
Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single‐center experience	14
Facing the challenges of very rare tumors of pediatric age: The European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) background, goals, and achievements	14
Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations	14
SARS‐CoV‐2 persistence in immunocompromised children	13
A systematic review and meta‐analytic evaluation of psychosocial interventions in parents of children with cancer with an exploratory focus on minority outcomes	13
SARS‐CoV‐2 in children with cancer in Brazil: Results of a multicenter national registry	13
Clinicopathological study of surgery for pulmonary metastases of hepatoblastoma with indocyanine green fluorescent imaging	13
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective	13
Parent perceptions of pediatric oncology care during the COVID‐19 pandemic: An Australian study	13
The intersectionality of gender and poverty on symptom suffering among adolescents with cancer	13
Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups	13
Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS)	13
Multilevel barriers and facilitators of communication in pediatric oncology: A systematic review	13
Current approaches to management of bone sarcoma in adolescent and young adult patients	13
Abstracts for PBC Volume 67, Supplement 5	13
Socioeconomic disparities in survival after high‐risk neuroblastoma treatment with modern therapy	13
High mortality of COVID‐19 in children with cancer in a single center in Algiers, Algeria	12
Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response	12
Omega 3 fatty acids can reduce early doxorubicin‐induced cardiotoxicity in children with acute lymphoblastic leukemia	12
Multidisciplinary Network ActiveOncoKids guidelines for providing movement and exercise in pediatric oncology: Consensus‐based recommendations	12
Building the ecosystem for pediatric neuro‐oncology care in Pakistan: Results of a 7‐year long twinning program between Canada and Pakistan	12
Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low‐risk clinical trials: A report from the Children's Oncology Group	12
Effect of time on quality of parent–child communication in pediatric cancer	12
Post‐COVID‐19 severe neutropenia	12
Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it	12
Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10‐year longitudinal study on the SPPIBA cohort	12
Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia	12
How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies	12
The European Paediatric Rare Tumours Network ‐ European Registry (PARTNER) project for very rare tumors in children	12
Psychosocial care providers’ perspectives: Barriers to implementing services for siblings of children with cancer	12
Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia	12
Late isolated central nervous system relapse in childhood B‐cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Ch	12
Clinical and molecular features of pediatric cancer patients with Lynch syndrome	12
Pediatric cancer care in Africa: SIOP Global Mapping Program report on economic and population indicators	12
Hematopoietic stem cell transplant referral patterns for children with sickle cell disease vary among pediatric hematologist/oncologists’ practice focus: A Sickle Cell Transplant Advocacy and Research	11
α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft‐versus‐host disease	11
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group	11
Real‐world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab	11
Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana‐Farber Cancer Institute ALL Consortium trial 05‐001	11
Hydroxyurea in children with sickle cell disease in a resource‐poor setting: Monitoring and effects of therapy. A practical perspective	11
Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL‐6/JAK inhibition: A pediatric case series	11
Location of end‐of‐life care of children with cancer: A systematic review of parent experiences	11
Abstracts from the 38^th Annual Meeting of the Histiocyte Society Held Virtually and In Person in Stockholm, Sweden from September 18‐20, 2022	11
Integrating irinotecan in standard chemotherapy: A novel dose‐density combination for high‐risk pediatric sarcomas	11
Association of psychological distress and religious coping tendencies in parents of children recently diagnosed with cancer: A cross‐sectional study	11
Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real‐world setting: Results from the NEUF study	11
Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors	11
Subsequent malignant neoplasms in the pediatric age in retinoblastoma survivors in Argentina	11
A scoping review of transition interventions for young adults with sickle cell disease	11
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group	11
Systemic juvenile xanthogranuloma: A systematic review	11
Determinants of delayed childhood cancer care in low‐ and middle‐income countries: A systematic review	11
Nocturnal hypertension associated with stroke and silent cerebral infarcts in children with sickle cell disease	11
Coagulation profiles and viscoelastic testing in multisystem inflammatory syndrome in children	11
Fusion transcripts as liquid biopsy markers in alveolar rhabdomyosarcoma and synovial sarcoma: A report of the Cooperative Weichteilsarkom Studiengruppe (CWS)	11
Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)	11
Unresectable thoracic neuroblastic tumors: Changes in image‐defined risk factors after chemotherapy and impact on surgical management	11
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma	11
Pyruvate kinase deficiency in children	11
Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)	11
Clonal dynamics in pediatric B‐cell precursor acute lymphoblastic leukemia with very early relapse	10
Poor diet quality and adverse eating behaviors in young survivors of childhood cancer	10

Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single‐center retrospective study	10
Feasibility of oncology clinical trial‐embedded evaluation of social determinants of health	10
Drug penetration in pediatric brain tumors: Challenges and opportunities	10
Prevalence and risk factors for vitamin D deficiency in long‐term childhood cancer survivors	10
Automating the treatment planning process for 3D‐conformal pediatric craniospinal irradiation therapy	10
Outcomes of Wilms tumor treatment in western Kenya	10
Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children	10
“Some things are even worse than telling a child he is going to die”: Pediatric oncology healthcare professionals perspectives on communicating with children about cancer and end of life	10
Neurocognitive functioning in preschool children with sickle cell disease	10
Follow‐up evaluation of a web‐based pediatric brain tumor board in Latin America	10
Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations	10
COVID‐19 in pediatric survivors of childhood cancer and hematopoietic cell transplantation from a single center in New York City	10
SARS‐CoV‐2 vaccine acceptability among caregivers of childhood cancer survivors	10
Immune thrombocytopenia secondary to COVID‐19 infection: Report of two cases	10
Home‐based cognitive behavioural therapy for families of young children with cancer (FAMOS): A nationwide randomised controlled trial	10
Effect of COVID‐19 on anakinra‐induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis	10
Daratumumab in T‐cell acute lymphoblastic leukaemia: A case report and review of the literature	10
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b‐precursor acute lymphoblastic leukaemia: Case reports and literature review	10
Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1‐associated optic pathway gliomas in children	10
Perceptions of parents of pediatric patients with acute lymphoblastic leukemia on oral chemotherapy administration: A qualitative analysis	10
Novel treatments for hemophilia through rebalancing of the coagulation cascade	10
Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow‐up for impact on health care‐associated infections	10
Quality assurance in radiation oncology	10
Salivary gland carcinoma in children and adolescents: The EXPeRT/PARTNER diagnosis and treatment recommendations	10
Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia	10
SARS‐CoV‐2‐related multisystem inflammatory syndrome in an immunocompromised child with leukemia	10
Late effects in survivors of high‐risk neuroblastoma following stem cell transplant with and without total body irradiation	10
Lidocaine infusions and reduced opioid consumption—Retrospective experience in pediatric hematology and oncology patients with refractory pain	10
Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children	10
Reduced‐intensity conditioning–based hematopoietic cell transplantation for dyskeratosis congenita: Single‐center experience and literature review	10
Pathogenic variants inPIK3CAare associated with clinical phenotypes of kaposiform lymphangiomatosis, generalized lymphatic anomaly, and central conducting lymphatic anomaly	9
Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients	9
Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study	9
Local control of parameningeal rhabdomyosarcoma: An expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT)	9
Pretransplant myeloid and immune suppression, reduced toxicity conditioning with posttransplant cyclophosphamide: Initial outcomes of novel approach for matched unrelated donor hematopoietic stem cell	9
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force	9
Online patient portal use by caregivers in pediatric oncology: Are we widening sociodemographic disparities?	9
Perceived barriers and facilitators to physical activity in childhood cancer survivors and their parents: A large‐scale interview study from the International PACCS Study	9
Potent antitumor effect of T cells armed with anti‐GD2 bispecific antibody	9
Is neutralization of IFN‐γ sufficient to control inflammation in HLH?	9
Navigating prognostic communication when children with poor‐prognosis cancer experience prolonged disease stability	9
Pediatric refractory immune thrombocytopenia: A systematic review	9
Efficacy of ready‐to‐use therapeutic food in malnourished children with cancer: Results of a randomized, open‐label phase 3 trial	9
COVID‐19 vaccine (mRNA BNT162b2) and COVID‐19 infection‐induced thrombotic thrombocytopenic purpura in adolescents	9
Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment	9
A global approach to long‐term follow‐up of targeted and immune‐based therapy in childhood and adolescence	9
Diagnosis and management of neutropenia in children: The approach of the Study Group on Neutropenia and Marrow Failure Syndromes of the Pediatric Italian Hemato‐Oncology Association (Associazione Ital	9
Living in an online world: Social media experiences of adolescents and young adults with cancer	9
Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation	9
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center	9
COVID‐19 among children with cancer in Greece (2020): Results from the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM‐ST)	9
Second cancer risk in childhood cancer survivors treated with intensity‐modulated radiation therapy: An updated analysis of more than 10 years of follow‐up	9
Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion‐dependent thalassemia: A	9
Non‐rhabdomyosarcoma soft‐tissue sarcoma	9
Pediatric oncology infrastructure and workforce training needs: A report from the Pediatric Oncology East and Mediterranean (POEM) Group	9
Low‐dose ketamine infusions reduce opioid use in pediatric and young adult oncology patients	9
Rhabdomyosarcoma of the female genitourinary tract: Primary and relapsed disease in infants and older children. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one	9
Resource‐appropriate selection of osteosarcoma treatment protocols in low‐ and middle‐income countries	9
Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome	9
Development and validation of a CT‐based radiomics signature for identifying high‐risk neuroblastomas under the revised Children's Oncology Group classification system	9
Implementation of near‐universal hydroxyurea uptake among children with sickle cell anemia: A single‐center experience	9
Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions	9
To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma	9
BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers	9
Volumetric modulated arc therapy total body irradiation in pediatric and adolescent/young adult patients undergoing stem cell transplantation: Early outcomes and toxicities	9
Response criteria for intraocular retinoblastoma: RB‐RECIST	9
Pulmonary embolism in pediatric and adolescent patients with COVID‐19 infection during the SARS‐CoV‐2 delta wave	9
Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients	9
Azacitidine and venetoclax for post‐transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia	9
ε‐Aminocaproic acid versus tranexamic acid in children undergoing complex cranial vault reconstruction for repair of craniosynostosis	8
Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004–2019	8
Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations	8
Health‐related quality of life, fatigue and health behaviours in Australian adolescent and young adult cancer survivors	8
Allergies, genetic polymorphisms of Th2 interleukins, and childhood acute lymphoblastic leukemia: The ESTELLE study	8
Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography	8
Communication with parents and young adult patients affected by complex vascular malformations	8
Autoimmune hemolytic anemia in children with COVID‐19	8
Associations between demographics and quality of life in children in the first year of cancer treatment	8
Should treatment of ALK‐positive anaplastic large cell lymphoma be stratified according to minimal residual disease?	8
Safety and efficacy of concurrent carboplatin during full‐dose craniospinal irradiation for high‐risk/metastatic medulloblastoma in a resource‐limited setting	8
Clear cell sarcoma of the kidney in Austrian children: Long‐term survival after relapse	8
De novo TP53 germline activating mutations in two patients with the phenotype mimicking Diamond–Blackfan anemia	8
Combinatorial effects of azacitidine and trametinib on NRAS‐mutated melanoma	8
Cutaneous adverse events in children treated with vemurafenib for refractory BRAF^V600E mutated Langerhans cell histiocytosis	8
How we approach genetics in the diagnosis and management of vascular anomalies	8
Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group	8
Cost‐effectiveness of home‐based care of febrile neutropenia in children with cancer	8
Kaposiform hemangioendothelioma of the bone in children and adolescents	8
Role of anticoagulation in the management of tumor thrombus: A 10‐year single‐center experience	8
“Don't be afraid to speak up”: Communication advice from parents and clinicians of children with cancer	8
Burden of central nervous system complications in sickle cell disease: A systematic review and meta‐analysis	8
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN‐amplified neuroblastoma	8
Comparison of transfusion reactions in children and adults: A systematic review and meta‐analysis	8
Outcomes of intensification of induction chemotherapy for children with high‐risk acute myeloid leukemia: A report from the Children's Oncology Group	8
Detrimental variants in MPIG6B in two children with myelofibrosis: Does immune dysregulation contribute to myelofibrosis?	8